Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Amortization of Deferred Charges (2016 - 2026)

Ocular Therapeutix has reported Amortization of Deferred Charges over the past 14 years, most recently at $1.4 million for Q1 2026.

  • For Q1 2026, Amortization of Deferred Charges fell 3.83% year-over-year to $1.4 million; the TTM value through Mar 2026 reached $3.3 million, up 4.37%, while the annual FY2025 figure was $3.4 million, 9.03% down from the prior year.
  • Amortization of Deferred Charges for Q1 2026 was $1.4 million at Ocular Therapeutix, up from $495000.0 in the prior quarter.
  • Over five years, Amortization of Deferred Charges peaked at $2.1 million in Q3 2023 and troughed at $495000.0 in Q4 2025.
  • A 5-year average of $1.1 million and a median of $1.2 million in 2022 define the central range for Amortization of Deferred Charges.
  • Biggest five-year swings in Amortization of Deferred Charges: soared 69.14% in 2023 and later plummeted 70.03% in 2024.
  • Year by year, Amortization of Deferred Charges stood at $1.2 million in 2022, then grew by 25.55% to $1.6 million in 2023, then crashed by 62.91% to $576000.0 in 2024, then decreased by 14.06% to $495000.0 in 2025, then soared by 178.99% to $1.4 million in 2026.
  • Business Quant data shows Amortization of Deferred Charges for OCUL at $1.4 million in Q1 2026, $495000.0 in Q4 2025, and $758000.0 in Q3 2025.